Global Biosynthetic Human Milk Oligosaccharides (HMOs) Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Biosynthetic Human Milk Oligosaccharides (HMOs) market size was valued at US$ 725 million in 2024 and is forecast to a readjusted size of USD 3212 million by 2031 with a CAGR of 24.0% during review period.
Biosynthetic Human Milk Oligosaccharides (HMOs) are complex carbohydrates naturally found in human breast milk that play a crucial role in infant nutrition and health. These oligosaccharides are not directly digestible by infants but act as prebiotics to promote the growth of beneficial gut bacteria, support immune function, and help develop a healthy gut microbiome. HMOs are one of the key components that differentiate human milk from the milk of other mammals, with over 200 different types of HMO identified in breast milk, whereas other mammalian milk contains only small amounts of HMOs.
In recent years, the biosynthetic production of HMOs has advanced, enabling the inclusion of these beneficial compounds in infant formulas. By mimicking the composition of human breast milk, biosynthetic HMOs aim to replicate the health benefits traditionally associated with breastfeeding. These biosynthetic HMOs are typically produced at a large scale using genetically engineered microbes through fermentation processes, overcoming the limitation of traditional dairy products that do not contain these important carbohydrates. 2'-Fucosyllactose (2'-FL) is a key HMO found in human milk and has been shown to play a significant role in gut health, immune system development, and protection against infections.
With the global increasing focus on infant health, immune function, and gut health, the market for biosynthetic HMOs is showing significant potential. In emerging markets such as China, India, and other regions, as living standards improve and greater attention is paid to infant health and nutrition, the demand for HMOs is steadily growing. As a natural ingredient found in breast milk, HMOs are seen as a way to mimic the beneficial components of breast milk, which has led to a broadening of their application scenarios. HMOs are not only widely used in infant formula but are also receiving growing attention in adult health, functional foods, and pharmaceuticals.
Furthermore, the growing recognition of the benefits of breastfeeding, coupled with increasing consumer awareness of infant health, contributes to the expanding market for biosynthetic HMOs. As biotechnology advances, production processes have become more cost-effective, further enhancing the market development potential.
Market Risks
Despite the promising market opportunities, the biosynthetic HMO industry faces several challenges. First, the production of HMOs is still relatively complex and costly. Although production techniques are improving, the price of HMOs remains relatively high compared to traditional dairy products, which may hinder their adoption in lower-income markets.
Second, there are high technological barriers in HMO production. The production process involves advanced biotechnologies such as genetic engineering and fermentation techniques, which means that only a few large companies and research institutions can effectively master these technologies, resulting in a relatively high level of market concentration.
Finally, with the market’s expansion, regulatory challenges may arise. HMOs have wide-ranging biological functions and applications, which may subject them to varying regulations in different countries and regions, creating uncertainty in market development.
Market Concentration
Currently, the biosynthetic HMO market has a high concentration, mainly dominated by a few companies with advanced production technologies. These companies typically have strong R&D capabilities and production facilities to ensure product quality and consistency. However, with the widespread adoption of biotechnology and the increase in competition, market dynamics are expected to become more competitive, providing opportunities for emerging companies to enter the market through technological innovations and cost management.
Downstream Demand Trends
The downstream demand for biosynthetic HMOs primarily comes from the infant formula market and the adult functional food market. The infant formula market remains the largest source of demand, and with global demographic changes and updated parenting practices, the demand for infant formula continues to grow. Additionally, with increasing consumer interest in health, the adult functional food market has also become an important application area for HMOs. Particularly in gut health, immune system enhancement, and neurological protection, HMOs as a functional food ingredient have tremendous market potential.
Latest Technologies
Recent technological advancements in the field of biosynthetic HMO production are centered around fermentation technology and genetic engineering applications. Fermentation technology has become an efficient and cost-effective method for producing HMOs. Through microbial fermentation, large quantities of HMOs can be produced in a relatively short period, and the production cost can be significantly reduced. Additionally, innovations in genetic engineering technologies have made the HMO synthesis process more precise, enabling the customization of specific types of HMOs to meet market demands for particular functions.
With ongoing advancements in technology, the production process for HMOs is expected to become even more streamlined, and production costs are likely to decline further, which will drive the widespread application of HMOs globally.
This report is a detailed and comprehensive analysis for global Biosynthetic Human Milk Oligosaccharides (HMOs) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market size and forecasts, in consumption value ($ Million), 2020-2031
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosynthetic Human Milk Oligosaccharides (HMOs)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosynthetic Human Milk Oligosaccharides (HMOs) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Dupont (Inbiose), DSM (Glycom), Chr. Hansen (Jennewein), BASF, FrieslandCampina, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biosynthetic Human Milk Oligosaccharides (HMOs) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
2'-FL & 3-FL
LNT & LNnT, etc.
Market segment by Application
Infant Formula
Other Applications
Market segment by players, this report covers
Abbott
Dupont (Inbiose)
DSM (Glycom)
Chr. Hansen (Jennewein)
BASF
FrieslandCampina
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biosynthetic Human Milk Oligosaccharides (HMOs) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biosynthetic Human Milk Oligosaccharides (HMOs), with revenue, gross margin, and global market share of Biosynthetic Human Milk Oligosaccharides (HMOs) from 2020 to 2025.
Chapter 3, the Biosynthetic Human Milk Oligosaccharides (HMOs) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Biosynthetic Human Milk Oligosaccharides (HMOs) market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biosynthetic Human Milk Oligosaccharides (HMOs).
Chapter 13, to describe Biosynthetic Human Milk Oligosaccharides (HMOs) research findings and conclusion.
Biosynthetic Human Milk Oligosaccharides (HMOs) are complex carbohydrates naturally found in human breast milk that play a crucial role in infant nutrition and health. These oligosaccharides are not directly digestible by infants but act as prebiotics to promote the growth of beneficial gut bacteria, support immune function, and help develop a healthy gut microbiome. HMOs are one of the key components that differentiate human milk from the milk of other mammals, with over 200 different types of HMO identified in breast milk, whereas other mammalian milk contains only small amounts of HMOs.
In recent years, the biosynthetic production of HMOs has advanced, enabling the inclusion of these beneficial compounds in infant formulas. By mimicking the composition of human breast milk, biosynthetic HMOs aim to replicate the health benefits traditionally associated with breastfeeding. These biosynthetic HMOs are typically produced at a large scale using genetically engineered microbes through fermentation processes, overcoming the limitation of traditional dairy products that do not contain these important carbohydrates. 2'-Fucosyllactose (2'-FL) is a key HMO found in human milk and has been shown to play a significant role in gut health, immune system development, and protection against infections.
With the global increasing focus on infant health, immune function, and gut health, the market for biosynthetic HMOs is showing significant potential. In emerging markets such as China, India, and other regions, as living standards improve and greater attention is paid to infant health and nutrition, the demand for HMOs is steadily growing. As a natural ingredient found in breast milk, HMOs are seen as a way to mimic the beneficial components of breast milk, which has led to a broadening of their application scenarios. HMOs are not only widely used in infant formula but are also receiving growing attention in adult health, functional foods, and pharmaceuticals.
Furthermore, the growing recognition of the benefits of breastfeeding, coupled with increasing consumer awareness of infant health, contributes to the expanding market for biosynthetic HMOs. As biotechnology advances, production processes have become more cost-effective, further enhancing the market development potential.
Market Risks
Despite the promising market opportunities, the biosynthetic HMO industry faces several challenges. First, the production of HMOs is still relatively complex and costly. Although production techniques are improving, the price of HMOs remains relatively high compared to traditional dairy products, which may hinder their adoption in lower-income markets.
Second, there are high technological barriers in HMO production. The production process involves advanced biotechnologies such as genetic engineering and fermentation techniques, which means that only a few large companies and research institutions can effectively master these technologies, resulting in a relatively high level of market concentration.
Finally, with the market’s expansion, regulatory challenges may arise. HMOs have wide-ranging biological functions and applications, which may subject them to varying regulations in different countries and regions, creating uncertainty in market development.
Market Concentration
Currently, the biosynthetic HMO market has a high concentration, mainly dominated by a few companies with advanced production technologies. These companies typically have strong R&D capabilities and production facilities to ensure product quality and consistency. However, with the widespread adoption of biotechnology and the increase in competition, market dynamics are expected to become more competitive, providing opportunities for emerging companies to enter the market through technological innovations and cost management.
Downstream Demand Trends
The downstream demand for biosynthetic HMOs primarily comes from the infant formula market and the adult functional food market. The infant formula market remains the largest source of demand, and with global demographic changes and updated parenting practices, the demand for infant formula continues to grow. Additionally, with increasing consumer interest in health, the adult functional food market has also become an important application area for HMOs. Particularly in gut health, immune system enhancement, and neurological protection, HMOs as a functional food ingredient have tremendous market potential.
Latest Technologies
Recent technological advancements in the field of biosynthetic HMO production are centered around fermentation technology and genetic engineering applications. Fermentation technology has become an efficient and cost-effective method for producing HMOs. Through microbial fermentation, large quantities of HMOs can be produced in a relatively short period, and the production cost can be significantly reduced. Additionally, innovations in genetic engineering technologies have made the HMO synthesis process more precise, enabling the customization of specific types of HMOs to meet market demands for particular functions.
With ongoing advancements in technology, the production process for HMOs is expected to become even more streamlined, and production costs are likely to decline further, which will drive the widespread application of HMOs globally.
This report is a detailed and comprehensive analysis for global Biosynthetic Human Milk Oligosaccharides (HMOs) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market size and forecasts, in consumption value ($ Million), 2020-2031
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Biosynthetic Human Milk Oligosaccharides (HMOs) market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosynthetic Human Milk Oligosaccharides (HMOs)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosynthetic Human Milk Oligosaccharides (HMOs) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Dupont (Inbiose), DSM (Glycom), Chr. Hansen (Jennewein), BASF, FrieslandCampina, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biosynthetic Human Milk Oligosaccharides (HMOs) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
2'-FL & 3-FL
LNT & LNnT, etc.
Market segment by Application
Infant Formula
Other Applications
Market segment by players, this report covers
Abbott
Dupont (Inbiose)
DSM (Glycom)
Chr. Hansen (Jennewein)
BASF
FrieslandCampina
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biosynthetic Human Milk Oligosaccharides (HMOs) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biosynthetic Human Milk Oligosaccharides (HMOs), with revenue, gross margin, and global market share of Biosynthetic Human Milk Oligosaccharides (HMOs) from 2020 to 2025.
Chapter 3, the Biosynthetic Human Milk Oligosaccharides (HMOs) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Biosynthetic Human Milk Oligosaccharides (HMOs) market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biosynthetic Human Milk Oligosaccharides (HMOs).
Chapter 13, to describe Biosynthetic Human Milk Oligosaccharides (HMOs) research findings and conclusion.
Table of Contents
93 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
